Keywords : multiple sclerosis, cancer
About This Report Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy. What's Included in This Rep...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
About This Report
Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy.
What's Included in This Report?
* Understand Datamonitor’s independent appraisal of industry ed brands and key pipeline agents indicated for treating multiple sclerosis.
* Illustrate how pipeline and industry ed drugs compare to one another in terms of clinical and commercial attributes.
* Assessment of the strengths, weaknesses, opportunities, and threats for key industry ed and pipeline therapies.
* Review of important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
* Determine to what extent current and future therapies satisfy the main clinical unmet needs in multiple sclerosis treatment.
Key Market Facts
Datamonitor’s recent survey reveals that US neurologists prescribe Gilenya because of its strong efficacy in treatment resistant patients as well as its convenient oral mode of administration. However, long term cancer and infection risk remain the main concerns.
The multiple sclerosis industry has been lucrative for drug industry players over the last decade with limited competition and periodic price increases. However, as this dynamic is changing with increased competition, existing players are grow ing their portfolios with new and improved therapies.
Monoclonal antibodies have demonstrated potent efficacy in Phase II trials, surpassing all existing therapies. However, excitement is tempered with safety concerns that include risk of malignancy and severe infections. Still, as seen with Tysabri, impressive efficacy may outweigh the risks for more severe multiple sclerosis patients.
Why Should You Buy This Report?
* How well do agents in late-stage development for multiple sclerosis compare to one another and the current standard of care?
* What is the most promising treatment in development for multiple sclerosis?
* How do US neurologists perceive Gilenya and key pipeline agents as new treatments of multiple sclerosis?
Pathology Industry in the United States
Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET OVERVIEW
Product overview
Datamonitor’s assessment summary
MARKETED PRODUCT PROFILES
Gilenya (fingolimod; Novartis/Mitsubishi Tanabe Pharma)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Physician perception of Gilenya
Clinical and commercial attractiveness
Avonex (interferon beta-1a; Biogen Idec)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Rebif (interferon beta-1a; Merck Serono)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Betaseron (interferon beta-1b; Bayer Schering)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Extavia (interferon beta-1a; Novartis)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Copaxone (glatiramer acetate; Teva)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Tysabri (natalizumab; Biogen Idec/Elan)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Ampyra (dalfampridine; Acorda Therapeutics/Biogen Idec/Elan)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Sativex (nabiximols; GW Pharmaceuticals)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Portfolio
Clinical and commercial attractiveness
Other industry ed drugs for multiple sclerosis
Novantrone (mitoxantrone; Merck Serono)
PIPELINE PRODUCT PROFILES
Movectro (cladribine; Merck Serono)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of Movectro
Clinical and commercial attractiveness
Monthly Avonex (PEGylated interferon beta-1a; Biogen Idec)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of monthly Avonex
Clinical and commercial attractiveness
BG-12 (dimethyl fumarate; Biogen Idec)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of BG-12
Clinical and commercial attractiveness
Laquinimod (Teva)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of laquinimod
Clinical and commercial attractiveness
Daclizumab (Biogen Idec/Abbott)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of daclizumab
Clinical and commercial attractiveness
Teriflunomide (HMR1726; Sanofi)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of teriflunomide
Clinical and commercial attractiveness
Lemtrada (alemtuzumab; Genzyme/Bayer Schering)
Drug presentation
Drug pipeline analysis
SWOT analysis
Satisfaction of unmet needs
Physician perception of Lemtrada
Clinical and commercial attractiveness
Ocrelizumab (R15-2477; Roche/Biogen Idec)
Drug presentation
Drug pipeline analysis
SWOT analysis
Physician perception of ocrelizumab
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other drugs in development for multiple sclerosis
Tovaxin (Opexa Therapeutics)
BHT-3009 (Bayhill Therapeutics)
Neurovax (Immune Response BioPharma)
Firategrast (GlaxoSmithKline)
ATL1102 (Isis Pharmaceuticals/Antisense Therapeutics)
BAF312 (Novartis)
Ponesimod (R-3477; Actelion)
ONO-4641 (Ono Pharmaceuticals)
Arzerra (ofatumumab; Genmab/GlaxoSmithKline)
LY2127399 (Eli Lilly)
Pleneva (BGC-20-0134; BTG)
IPX056 (baclofen controlled release; Impax Laboratories)
MCT-125 (lofepramine and L-phenylalanine; Multicell Technologies)
BIBLIOGRAPHY
Journal papers
Websites
Other sources
Datamonitor reports
APPENDIX A
Datamonitor drug assessment scorecard
Physician research methodology
Physician sample breakdown
The survey questionnaire
Introduction
Section 1: Unmet Needs
Section 2: Influencing factors on prescribing
Section 3: New therapies entering Multiple Sclerosis
Demographics
APPENDIX B
Industry definition
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
